ArticleQuantitative imaging in medicine and surgery2026
Accelerated susceptibility-driven positive contrast MRI reconstruction based on primal-dual optimization with minimal parameter tuning.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metallic interventional devices such as brachytherapy seeds and stents, are extensively utilized in clinical settings. However, these devices generate significant susceptibility artifacts in conventional magnetic resonance imaging (MRI), manifesting as signal voids that impede precise visualization. Susceptibility-driven positive contrast MRI (PC-MRI) mitigates this limitation by solving regularized ℓ1-norm minimization problems to reconstruct positive contrast images. The conventional nonlinear conjugate gradient (CG) algorithm, commonly employed for solving such non-smooth convex optimization problems, encounters challenges, including slow convergence rates, sensitivity to initial solutions and parameter selection, and difficulties in achieving optimal imaging reconstruction due to ill-posed inversion problems. This study aimed to develop and evaluate an accelerated primal-dual (PD) optimization framework with graphics processing unit (GPU) parallelization to overcome the limitations of the conventional CG algorithm for susceptibility-driven PC-MRI reconstruction. The proposed method seeks to solve the exact ℓ1-minimization problem without smoothing approximations. Methods: The efficacy of the method was evaluated through computational simulations, phantom experiments, and Results: Comparing to the conventional CG method, the PD approach can provide a faster reconstruction convergence rate of 2-4 times, and it demonstrated an end-to-end easy-adjustment method that does not rely on parameter tuning. The results also show that the PD method achieves better visualization and more accurate localization of the metallic interventional devices in positive contrast. Quantitative evaluations showed that the PD method achieved a significant reduction in FWHM near metallic seeds (e.g., from 1.15 for CG to 1.02 for PD in Patient 2, 11.3% improvement, P<0.01), indicating superior image sharpness. A notable improvement in SNR was also observed (e.g., from 110.34 for CG to 131.65 for PD in Patient 2, 19.3% enhancement, P<0.01), confirming enhanced image quality in both phantom and Conclusions: The susceptibility-driven positive contrast imaging technique based on PD regularization demonstrates faster convergence, superior image quality, and easier parameter adjustment compared to conventional CG methods. The speed of reconstruction can be further improved by GPU acceleration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.